Adaptimmune Therapeutics Plc (ADAP) — Strategic Asset Allocation Index
Adaptimmune Therapeutics Plc (ADAP) has a Strategic Asset Allocation Index of 83.8% as of September 2023. Strategic assets (PP&E of $73.87 Million plus long-term investments of $-) total $73.87 Million, measured against net assets of $88.13 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See net asset quality index of Adaptimmune Therapeutics Plc to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Adaptimmune Therapeutics Plc Strategic Asset Allocation Index (2013–2022)
This chart shows how Adaptimmune Therapeutics Plc's Strategic Asset Allocation Index has evolved across 10 annual periods from 2013 to 2022. As of September 2023, the index stands at 83.8%, representing strategic assets of $73.87 Million against net assets of $88.13 Million USD. For live market cap and overall valuation, see ADAP stock market capitalisation.
Annual Strategic Asset Allocation Index for Adaptimmune Therapeutics Plc (2013–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Adaptimmune Therapeutics Plc from 2013 to 2022, covering 10 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See shareholders equity of Adaptimmune Therapeutics Plc for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 87.4% | $71.53 Million | $71.53 Million | $- | $81.88 Million | ▲ +72.6 pp |
| 2021 | 14.8% | $30.49 Million | $30.49 Million | $- | $205.96 Million | ▲ +6.7 pp |
| 2020 | 8.1% | $27.78 Million | $27.78 Million | $- | $341.23 Million | ▼ -17.0 pp |
| 2019 | 25.1% | $31.07 Million | $31.07 Million | $- | $123.64 Million | ▲ +10.5 pp |
| 2018 | 14.6% | $36.12 Million | $36.12 Million | $- | $246.88 Million | ▼ -5.4 pp |
| 2017 | 20.0% | $40.68 Million | $40.68 Million | $- | $202.98 Million | ▲ +3.2 pp |
| 2016 | 16.8% | $27.90 Million | $27.90 Million | $- | $166.14 Million | ▲ +11.7 pp |
| 2015 | 5.1% | $13.22 Million | $13.22 Million | $- | $259.61 Million | ▲ +3.0 pp |
| 2014 | 2.1% | $5.39 Million | $5.39 Million | $- | $259.61 Million | ▼ -57.5 pp |
| 2013 | 59.6% | $1.44 Million | $1.44 Million | $- | $2.41 Million | — |